Welcome!

News Feed Item

Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02256135/Lower-Limb-Muscle-Spasticity-Global-Clinical-Trials-Review-H2-2014.html

Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014" provides data on the Lower Limb Muscle Spasticity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lower Limb Muscle Spasticity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lower Limb Muscle Spasticity. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Lower Limb Muscle Spasticity 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10

Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials by E7 Countries: Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials 16
Clinical Trials by Phase in E7 Countries 17
Clinical Trials in E7 Countries by Trial Status 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20

Clinical Trials by Trial Status 21
Clinical Trials by End Point Status 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Lower Limb Muscle Spasticity Therapeutics Clinical Trials 26
Prominent Drugs 27
Clinical Trial Profiles 28
Clinical Trial Overview of Top Companies 28
Merz Pharma GmbH & Co. KgaA 28
Clinical Trial Overview of Merz Pharma GmbH & Co. KgaA 28
Ipsen S.A. 29
Clinical Trial Overview of Ipsen S.A. 29
Allergan, Inc. 30
Clinical Trial Overview of Allergan, Inc. 30
GlaxoSmithKline plc 31
Clinical Trial Overview of GlaxoSmithKline plc 31
Clinical Trial Overview of Top Institutes / Government 32
The University of Tokushima 32
Clinical Trial Overview of The University of Tokushima 32

Tehran University of Medical Sciences 33
Clinical Trial Overview of Tehran University of Medical Sciences 33
Danish Pain Research Center 34
Clinical Trial Overview of Danish Pain Research Center 34
Assistance Publique Hopitaux De Marseille 35
Clinical Trial Overview of Assistance Publique Hopitaux De Marseille 35
Five Key Clinical Profiles 36
Appendix 112
Abbreviations 112
Definitions 112
Research Methodology 113
Secondary Research 113
About GlobalData 114
Contact Us 114
Disclaimer 114
Source 114

List of Tables

Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Region, 2014* 6
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 9
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 12

Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 13
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Lower Limb Muscle Spasticity Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 17
Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 18
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Phase, 2014* 19
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 20
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23

Lower Limb Muscle Spasticity Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 24
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Merz Pharma GmbH & Co. KgaA, 2014* 28
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Ipsen S.A., 2014* 29
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2014* 30
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 31
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Tokushima, 2014* 32
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 33
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Danish Pain Research Center, 2014* 34
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique Hopitaux De Marseille, 2014* 35

List of Figures

Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 9
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 12
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Lower Limb Muscle Spasticity Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 17

Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 18
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Phase (%), 2014* 19
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 20
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Lower Limb Muscle Spasticity Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 24
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
GlobalData Methodology 113

To order this report: Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02256135/Lower-Limb-Muscle-Spasticity-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Sometimes I write a blog just to formulate and organize a point of view, and I think it’s time that I pull together the bounty of excellent information about Machine Learning. This is a topic with which business leaders must become comfortable, especially tomorrow’s business leaders (tip for my next semester University of San Francisco business students!). Machine learning is a key capability that will help organizations drive optimization and monetization opportunities, and there have been some...
"Storpool does only block-level storage so we do one thing extremely well. The growth in data is what drives the move to software-defined technologies in general and software-defined storage," explained Boyan Ivanov, CEO and co-founder at StorPool, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Is advanced scheduling in Kubernetes achievable?Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, answered these questions and demonstrated techniques for implementing advanced scheduling. For example, using spot instances and co...
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.
The need for greater agility and scalability necessitated the digital transformation in the form of following equation: monolithic to microservices to serverless architecture (FaaS). To keep up with the cut-throat competition, the organisations need to update their technology stack to make software development their differentiating factor. Thus microservices architecture emerged as a potential method to provide development teams with greater flexibility and other advantages, such as the abili...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...